CSL slumped to a nine-year low after warning of lower full-year revenue guidance and announcing a $5 billion impairment charge. The company linked the update to a revised outlook that includes the new impairment, raising questions for shareholders about underlying asset or business-line valuation. The market reaction highlights how reimbursement, product mix, and accounting impacts can quickly pressure large biopharma even amid ongoing pipeline investment.